Mazdutide
A GLP-1 and glucagon dual agonist developed with Innovent and Lilly, notable for obesity data and approval progress in China.
Also referenced as: IBI362, LY3305677
Also appears in: Hormone
This compound has a genuine development or study trail, but it is not an approved routine drug.
Primary lane: Weight Loss. Also surfaces under Hormone for browsing and discovery.
IBI362, LY3305677
No FDA label signal · 33 trials · 40 PubMed results
What mazdutide is
Mazdutide is a GLP-1 / glucagon dual receptor agonist developed by Innovent and Lilly, best known right now for obesity and metabolic-disease development in China.
Why it matters
It belongs in the same broad family as other dual-agonist obesity drugs, but it matters on its own because it already has a meaningful clinical literature and has moved farther commercially in China than many pipeline names discussed in U.S.-centric peptide circles.
Regulatory context
Mazdutide is not FDA approved in the United States. It is best understood as an important international obesity-pipeline drug rather than an established U.S. therapy.
Practical reading note
Mazdutide is useful because it helps the library track not just what is popular in the U.S. market, but what is becoming important globally.